{'Year': '2011', 'Month': 'Mar'}
Pharmacogenetics: Anti-TNF therapy in RA--towards personalized medicine?
A substantial proportion of patients with rheumatoid arthritis do not respond to tumor necrosis factor blocking therapy. Results of a large genome-wide association study demonstrate evidence of novel genetic factors that determine response to treatment, which could provide a basis for individualizing therapy.